FDA Approves Safer Dosing Regimen for Eli Lilly’s Alzheimer’s Drug Kisunla

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-07-10 19:34:02

BTCCSquare news:

Eli Lilly shares gained 1.19% to $786.92 after regulators approved an updated label for its Alzheimer's treatment. The new titration protocol reduces brain swelling risks by up to 41% while preserving therapeutic benefits, according to Phase 3 trial data.

The modified dosing schedule delays administration of one vial until the third infusion, maintaining cumulative drug exposure while cutting ARIA-E incidence from 24% to 14% at six months. Safety improvements come without compromising Kisunla's ability to slow cognitive decline in early-stage patients.

Lilly's stock has quadrupled since 2019 despite recent volatility, reflecting investor confidence in the pharma giant's neurology pipeline. The label update strengthens Kisunla's competitive position against rival amyloid-targeting therapies.

By:

Log in to Reply

US Treasury Officially Scraps Crypto Broker Reporting Rules After Congressional Vote

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.